Cypherpunk Technologies, the Zcash (ZEC) treasury company backed by Cameron and Tyler Winklevoss, is facing a difficult financial crossroads after reporting a $37.8 million net loss for the first six months of 2026. The company holds roughly $157 million worth of ZEC, yet its market value remains far below the value of those crypto assets.

At the same time, its cancer drug candidate is approaching an expensive Phase 3 trial that Cypherpunk admits will require significant additional funding. The result is a growing tension between its crypto treasury strategy and its ambition to develop a potential cancer treatment.

As of June 30, Cypherpunk held 323,394 ZEC, representing about 1.92% of the circulating supply, with an average purchase price of roughly $341.83 per coin.

Despite accumulating a sizable Zcash position, the company’s shares have traded at a substantial discount to the value of its underlying crypto assets. Cypherpunk’s basic market-value-to-net-asset-value multiple stood at around 0.47x, while its adjusted enterprise-value mNAV, which includes pre-funded warrants and other instruments, was approximately 0.96x.

In other words, investors are valuing the company at less than the value of the assets sitting on its balance sheet.

The disconnect has become even more striking as Cypherpunk’s stock continues to struggle. Shares have fallen roughly 40% since the start of 2026 and about 96% over the past five years, despite ZEC itself holding relatively steady over the same period.

The performance is a sharp departure from the ambition laid out by Tyler Winklevoss when the treasury strategy launched. He said the company intended to accumulate ZEC rapidly enough to eventually own at least 5% of the cryptocurrency’s total supply.

Nine months later, Cypherpunk owns less than 2%.

While the Zcash treasury has struggled to generate the equity valuation the company hoped for, Cypherpunk is also confronting a much more expensive challenge in biotechnology.

Its lead cancer drug candidate, sirexatamab, an anti-DKK1 antibody, failed to beat the control arm on progression-free survival across all patients in a randomized Phase 2 trial. Cypherpunk attributed the result to what it described as an underpowered final analysis.

The setback has not ended the program. In May, the US Food and Drug Administration granted sirexatamab Fast Track designation, while regulators agreed on the design of a roughly 270-patient Phase 3 trial targeting colorectal cancer.

But getting there will require money Cypherpunk does not currently have in abundance.

Management said it is conducting a strategic process to determine the best way to advance sirexatamab, including potentially creating an independently financed spinout or partnering with another company.

That could allow Cypherpunk to pursue the drug without placing the entire financial burden on its existing balance sheet.

The funding challenge becomes clearer in Cypherpunk’s latest financial position.

The company had just $7.6 million in cash and cash equivalents as of June 30, while carrying more than half a billion dollars in accumulated deficits and continuing to generate operating losses.

Cypherpunk warned that it “expects to continue to generate operating losses for the foreseeable future” and indicated that, unless ZEC appreciates substantially, it will need to raise significant additional capital to fund its operations and upcoming clinical trials.

That leaves the company balancing two very different bets.

Its Zcash holdings give Cypherpunk a substantial crypto treasury, but the stock market continues to value the company below those assets. Meanwhile, its cancer drug could provide an entirely different source of value, but advancing it through Phase 3 and toward potential FDA approval could require substantial new investment.

For now, Cypherpunk’s future appears increasingly dependent on its ability to unlock value from one side of the business without starving the other of capital. Whether that comes through a ZEC rally, new equity financing, a pharmaceutical partnership or a separate company for sirexatamab could determine whether the Winklevoss-backed experiment can turn its unusual combination of crypto and biotech assets into a viable business.